How long do you need to take Nintedanib/Vigat and what is the treatment plan?

Nintedanib is used to treat idiopathic pulmonary fibrosis (IPF) and other fibrosis-related diseases. The treatment plan and dosage need to be adjusted according to the patient's specific condition.

1. Daily dose: The usual recommended dose of nintedanib is 150 mg twice daily. Patients should ensure that the interval between doses is approximately 12 hours.

2. How to take: Nintedanib should be taken with food to reduce gastrointestinal discomfort. Food can help with drug absorption and reduce possible adverse effects, especially gastrointestinal effects such as nausea and vomiting.

3. Maximum dose: The patient's total daily dose should not exceed300mg (i.e. 150mg taken twice a day). Exceeding this dose may increase the risk of side effects.

Nintedanib treatment is usually long-term, especially in patients with idiopathic pulmonary fibrosis (IPF). The purpose of treatment is to slow the progression of the disease and prolong the patient's survival. Based on clinical experience and research data, patients usually need long-term use of nintedanib to control their condition, and their effects and adverse reactions need to be monitored regularly during use.

Although nintedanib is usually used for a longer period of time, patients may adjust their medication regimen during treatment based on factors such as drug tolerance, efficacy, and adverse reactions. During use, the doctor will evaluate whether the dosage needs to be adjusted or discontinued based on the patient's specific condition and treatment response.

The treatment plan for nintedanib is to take 150mg twice daily with a total dose not to exceed 300mg. Treatment usually requires long-term maintenance, especially for patients with idiopathic pulmonary fibrosis, and the goals of treatment are to slow disease progression and improve quality of life. Patients need to undergo regular follow-up and examinations according to the doctor's recommendations.

Keyword tags: nintedanib, Nintedanib, treatment regimen, idiopathic pulmonary fibrosis, pulmonary fibrosis, dose, medication time, treatment duration

Reference materials:https://www.medicines.org.uk/emc/product/1786/smpc